Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,730.58 -2,168.85 (-3.45%) CMC Crypto 200
1,261.13 -96.88 (-7.13%)
Moderna, Inc. (MRNA)
After hours:
| Previous close | 122.69 |
| Open | 120.75 |
| Bid | 117.27 x 400 |
| Ask | 117.38 x 400 |
| Day's range | 116.73 - 124.90 |
| 52-week range | 62.55 - 142.79 |
| Volume | |
| Avg. volume | 3,879,669 |
| Market cap | 47.02B |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.60 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 138.52 |
Yahoo FinanceNovavax stock doubles after Sanofi deal marks 'new chapter' for company
Novavax stock popped Friday on news of a licensing deal and minority stake from Big Pharma player Sanofi.
Barrons.comFDA Delays Decision on Moderna RSV Shot by 3 Weeks
The agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the drug’s safety, efficacy, or quality.
- Reuters
US FDA pushes decision on Moderna's RSV vaccine to end of this month
The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative constraints", the company said on Friday. The FDA's move prolongs the wait for Moderna's second approved product, but the company said it remains on track to be reviewed by a panel of advisers at the U.S. Centers for Disease Control and Prevention (CDC) on June 26 and 27. The CDC panel is expected to vote on recommendations for the vaccine's use and the intended population at the meeting, and success there is necessary for commercial launch.
